Blood cancer breakthrough? new biomarkers could predict deadly transplant complication
NCT ID NCT07305090
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find biological markers (biomarkers) that can predict how well patients will respond to treatment for a serious complication called gut graft-versus-host disease (GvHD) after a stem cell transplant for blood cancer. Researchers will collect samples from 90 patients aged 12 and older to build a tool that helps doctors personalize treatment. The goal is to improve survival and quality of life by identifying high-risk patients early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLOOD CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
RECRUITINGBologna, Bologna, 40138, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- Can donor immune cells be engineered to fight blood cancer?
- Can a new tracer light up cancer growth?
- Could a walk a day keep brain fog away after a stem cell transplant?